These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35863300)

  • 1. Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective.
    Langmia IM; Just KS; Yamoune S; Müller JP; Stingl JC
    Br J Clin Pharmacol; 2022 Dec; 88(12):5149-5165. PubMed ID: 35863300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.
    Molero P; Ramos-Quiroga JA; Martin-Santos R; Calvo-Sánchez E; Gutiérrez-Rojas L; Meana JJ
    CNS Drugs; 2018 May; 32(5):411-420. PubMed ID: 29736744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy: Ketamine and Esketamine.
    Feeney A; Papakostas GI
    Psychiatr Clin North Am; 2023 Jun; 46(2):277-290. PubMed ID: 37149345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity.
    Nguyen TML; McGowan JC; Gardier AM
    Neuropharmacology; 2022 Mar; 206():108936. PubMed ID: 34965407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J; Kawalec P; Pilc A
    Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of ketamine and esketamine in treatment of depression.
    Nikayin S; Murphy E; Krystal JH; Wilkinson ST
    Expert Opin Drug Saf; 2022 Jun; 21(6):777-787. PubMed ID: 35416105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions.
    Andrade C
    J Clin Psychiatry; 2017 Jul; 78(7):e858-e861. PubMed ID: 28858450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
    Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
    CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 in Pharmacogenetics: An Update.
    Tornio A; Backman JT
    Adv Pharmacol; 2018; 83():3-32. PubMed ID: 29801580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 15. Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study.
    Matłoka M; Janowska S; Gajos-Draus A; Ziółkowski H; Janicka M; Perko P; Kamil K; Pankiewicz P; Moszczyński-Pętkowski R; Mach M; Dera P; Abramski K; Teska-Kamińska M; Tratkiewicz E; Wieczorek M; Pieczykolan J
    Pulm Pharmacol Ther; 2022 Jun; 73-74():102127. PubMed ID: 35429651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.
    Zhu W; Ding Z; Zhang Y; Shi J; Hashimoto K; Lu L
    Neurosci Bull; 2016 Dec; 32(6):557-564. PubMed ID: 27878517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal esketamine: A novel drug for treatment-resistant depression.
    Khorassani F; Talreja O
    Am J Health Syst Pharm; 2020 Aug; 77(17):1382-1388. PubMed ID: 32729898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esketamine-A quick-acting novel antidepressant without the disadvantages of ketamine.
    Shoib S; Kotra M; Javed S; Nguyen VS; Malathesh BC
    Horm Mol Biol Clin Investig; 2022 Dec; 43(4):505-511. PubMed ID: 35851448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.
    Peltoniemi MA; Hagelberg NM; Olkkola KT; Saari TI
    Clin Pharmacokinet; 2016 Sep; 55(9):1059-77. PubMed ID: 27028535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.